Imran Mohd, Eltaib Lina, Siddique Muhammad Irfan, Kamal Mehnaz, Asdaq Syed Mohammed Basheeruddin, Singla Neelam, Al-Hajeili Marwan, Alhakami Fatemah Abdulaziz, AlQarni Ahmed Farhan, Abdulkhaliq Altaf A, Rabaan Ali A
Department of Pharmaceutical Chemistry, College of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
Department of Pharmaceutical Chemistry, College of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
Pathol Res Pract. 2024 Apr;256:155226. doi: 10.1016/j.prp.2024.155226. Epub 2024 Feb 28.
Urologic cancers (UCs), which include bladder, kidney, and prostate tumors, account for almost a quarter of all malignancies. Long non-coding RNAs (lncRNAs) are tissue-specific RNAs that influence cell growth, death, and division. LncRNAs are dysregulated in UCs, and their abnormal expression may allow them to be used in cancer detection, outlook, and therapy. With the identification of several novel lncRNAs and significant exploration of their functions in various illnesses, particularly cancer, the study of lncRNAs has evolved into a new obsession. MALAT1 is a flexible tumor regulator implicated in an array of biological activities and disorders, resulting in an important research issue. MALAT1 appears as a hotspot, having been linked to the dysregulation of cell communication, and is intimately linked to cancer genesis, advancement, and response to treatment. MALAT1 additionally operates as a competitive endogenous RNA, binding to microRNAs and resuming downstream mRNA transcription and operation. This regulatory system influences cell growth, apoptosis, motility, penetration, and cell cycle pausing. MALAT1's evaluation and prognosis significance are highlighted, with a thorough review of its manifestation levels in several UC situations and its association with clinicopathological markers. The investigation highlights MALAT1's adaptability as a possible treatment target, providing fresh ways for therapy in UCs as we integrate existing information The article not only gathers current knowledge on MALAT1's activities but also lays the groundwork for revolutionary advances in the treatment of UCs.
泌尿系统癌症（UCs），包括膀胱癌、肾癌和前列腺癌，占所有恶性肿瘤的近四分之一。长链非编码RNA（lncRNAs）是影响细胞生长、死亡和分裂的组织特异性RNA。lncRNAs在UCs中表达失调，其异常表达可能使其可用于癌症检测、预后评估和治疗。随着几种新型lncRNAs的鉴定以及对其在各种疾病（尤其是癌症）中功能的大量探索，lncRNAs的研究已发展成为一个新的热门领域。MALAT1是一种灵活的肿瘤调节因子，涉及一系列生物活性和疾病，这成为一个重要的研究课题。MALAT1似乎是一个热点，与细胞通讯失调有关，并且与癌症的发生、发展及对治疗的反应密切相关。MALAT1还作为一种竞争性内源性RNA发挥作用，与微小RNA结合并恢复下游mRNA的转录和功能。这种调节系统影响细胞生长、凋亡、迁移、侵袭以及细胞周期停滞。文中强调了MALAT1的评估和预后意义，并全面回顾了其在几种UC情况下的表达水平及其与临床病理标志物的关联。该研究突出了MALAT1作为一种潜在治疗靶点的适用性，在整合现有信息的同时为UCs的治疗提供了新途径。本文不仅收集了关于MALAT1活性的当前知识，还为UCs治疗的革命性进展奠定了基础。
